Osimertinib

Abstract

Thrombocytopenia and leucopenia: 2 case reports In a retrospective study of 84 patients, treated from September 2016 to March 2018, 2 patients [ages and sexes not stated] were described, who developed thrombocytopenia or leucopenia during treatment with osimertinib for advanced non-small cell lung cancer (NSCLC) [routes, durations of treatments to reactions onsets and outcomes not stated]. The patients, who had advanced NSCLS, received treatment with osimertinib 80 mg/time once daily. However, the patients developed leucopenia (1 patient) and thrombocytopenia (1 patient) secondary to the osimertinib therapy.